Prospect and progress of personalized peptide vaccinations for advanced cancers

References

• Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst. 2012;104:599–613. doi:10.1093/jnci/djs033.
   PubMed Web of Science ®Google Scholar
• Itoh K, Yamada A, Mine T, et al. Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol. 2009;39:73–80. doi:10.1093/jjco/hyn132.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422. doi:10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454. doi:10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465. doi:10.1056/NEJMoa1200694.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330. doi:10.1056/NEJMoa1412082.
   PubMed Web of Science ®Google Scholar
• Sasada T, Komatsu N, Suekane S, et al. Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. Eur J Cancer. 2010;46:1514–1519. doi:10.1016/j.ejca.2010.03.013.
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–1647.
   PubMed Web of Science ®Google Scholar
• Singh-Jasuja H, Emmerich NP, Rammensee HG. The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother. 2004;53:187–195. doi:10.1007/s00262-003-0480-x.
   PubMed Web of Science ®Google Scholar
• Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia. 2007;21:1859–1874. doi:10.1038/sj.leu.2404787.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323–5337. doi:10.1158/1078-0432.CCR-09-0737.
   PubMed Web of Science ®Google Scholar
• Avogadri F, Merghoub T, Maughan MF, et al. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One. 2010;5(9):e12670. doi:10.1371/journal.pone.0012670.
   PubMed Web of Science ®Google Scholar
• Hong S, Qian J, Li H, et al. CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol Immunother. 2012;61:561–571. doi:10.1007/s00262-011-1123-2.
   PubMed Web of Science ®Google Scholar
• Hu X, Chakraborty NG, Sporn JR, et al. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 1996;56:2479–2483.
   PubMed Web of Science ®Google Scholar
• Yamada A, Sasada T, Noguchi M, et al. Next-generation peptide vaccines for advanced cancer. Cancer Sci. 2013;104:15–21. doi:10.1111/cas.12050.
   PubMed Web of Science ®Google Scholar
• Perez SA, Von Hofe E, Kallinteris NL, et al. A new era in anticancer peptide vaccines. Cancer. 2010;116:2071–2080. doi:10.1002/cncr.24988.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Sherry RM, Morton KE, et al. Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. J Immunother. 2006;29:224–231. doi:10.1097/01.cji.0000190399.98802.10.
   PubMed Web of Science ®Google Scholar
• Terasaki M, Shibui S, Narita Y, et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen–A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol. 2011;29:337–344. doi:10.1200/JCO.2010.29.7499.
   PubMed Web of Science ®Google Scholar
• Yajima N, Yamanaka R, Mine T, et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res. 2005;11:5900–5911. doi:10.1158/1078-0432.CCR-05-0559.
   PubMed Web of Science ®Google Scholar
• Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci. 2006;97:970–976. doi:10.1111/j.1349-7006.2006.00272.x.
   PubMed Web of Science ®Google Scholar
• Hida N, Maeda Y, Katagiri K, et al. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother. 2002;51:219–228. doi:10.1007/s00262-002-0273-7.
   PubMed Web of Science ®Google Scholar
• Tsuda N, Mochizuki K, Harada M, et al. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother. 2004;27:60–72.
   PubMed Web of Science ®Google Scholar
• Mine T, Gouhara R, Hida N, et al. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci. 2003;94:548–556.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Harada M, Mine T, et al. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery. J Immunother. 2003;26:357–366.
   PubMed Web of Science ®Google Scholar
• Sharma P, Wagner K, Wolchok JD, et al. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11:805–812. doi:10.1038/nrc3153.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Immune monitoring of clinical trials with biotherapies. Adv Clin Chem. 2008;45:75–97.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Mine T, Komatsu N, et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther. 2010;10:1266–1279.
   PubMed Web of Science ®Google Scholar
• Komatsu N, Shichijo S, Nakagawa M, et al. New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest. 2004;64:535–545. doi:10.1080/00365510410007008.
   PubMed Web of Science ®Google Scholar
• Mine T, Sato Y, Noguchi M, et al. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res. 2004;10:929–937.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Uemura H, Naito S, et al. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate. 2011;71:470–479. doi:10.1002/pros.21261.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Kobayashi K, Suetsugu N, et al. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate. 2003;57:80–92. doi:10.1002/pros.10276.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Itoh K, Suekane S, et al. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate. 2004;60:32–45. doi:10.1002/pros.20011.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Itoh K, Suekane S, et al. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci. 2004;95:77–84.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Itoh K, Yao A, et al. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate. 2005;63:1–12. doi:10.1002/pros.20157.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Mine T, Yamada A, et al. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. Oncol Res. 2007;16:341–349.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Kakuma T, Uemura H, et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother. 2010;59:1001–1009. doi:10.1007/s00262-010-0822-4.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Moriya F, Suekane S, et al. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate. 2012;72:834–845. doi:10.1002/pros.21485.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Yao A, Harada M, et al. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate. 2007;67:933–942. doi:10.1002/pros.20572.
   PubMed Web of Science ®Google Scholar
• Yanagimoto H, Mine T, Yamamoto K, et al. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci. 2007;98:605–611. doi:10.1111/j.1349-7006.2007.00429.x.
   PubMed Web of Science ®Google Scholar
• Yanagimoto H, Shiomi H, Satoi S, et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep. 2010;24:795–801.
   PubMed Web of Science ®Google Scholar
• Yutani S, Komatsu N, Yoshitomi M, et al. A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. Oncol Rep. 2013;30:1094–1100. doi:10.3892/or.2013.2556.
   PubMed Web of Science ®Google Scholar
• Yoshitomi M, Yutani S, Matsueda S, et al. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med. 2012;3:463–469. doi:10.3892/etm.2011.424.
   PubMed Web of Science ®Google Scholar
• Sato Y, Shomura H, Maeda Y, et al. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci. 2003;94:802–808.
   PubMed Web of Science ®Google Scholar
• Sato Y, Fujiwara T, Mine T, et al. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci. 2007;98:1113–1119. doi:10.1111/j.1349-7006.2007.00498.x.
   PubMed Web of Science ®Google Scholar
• Sato Y, Maeda Y, Shomura H, et al. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br J Cancer. 2004;90:1334–1342. doi:10.1038/sj.bjc.6601711.
   PubMed Web of Science ®Google Scholar
• Hattori T, Mine T, Komatsu N, et al. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother. 2009;58:1843–1852. doi:10.1007/s00262-009-0695-6.
   PubMed Web of Science ®Google Scholar
• Kibe S, Yutani S, Motoyama S, et al. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer. Cancer Immunol Res. 2014;2:1154–1162. doi:10.1158/2326-6066.CIR-14-0035.
   PubMed Web of Science ®Google Scholar
• Yoshiyama K, Terazaki Y, Matsueda S, et al. Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol. 2012;40:1492–1500. doi:10.3892/ijo.2012.1351.
   PubMed Web of Science ®Google Scholar
• Yamada T, Terazaki Y, Sakamoto S, et al. Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens. Int J Oncol. 2015;46:55–62. doi:10.3892/ijo.2014.2699.
   PubMed Web of Science ®Google Scholar
• Terazaki Y, Yoshiyama K, Matsueda S, et al. Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer. Cancer Sci. 2012;103:638–644. doi:10.1111/j.1349-7006.2012.02202.x.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Noguchi M, Satoh T, et al. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int. 2011;108:831–838. doi:10.1111/j.1464-410X.2010.09933.x.
   PubMed Web of Science ®Google Scholar
• Suekane S, Nishitani M, Noguchi M, et al. Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci. 2007;98:1965–1968. doi:10.1111/j.1349-7006.2007.00631.x.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Matsumoto K, Uemura H, et al. An open-label, randomized phase II trial of personalized peptide vaccination in patients with bladder cancer that progressed after platinum-based chemotherapy. Clin Cancer Res. 2016;22:54–60. doi:10.1158/1078-0432.CCR-15-1265.
   PubMed Web of Science ®Google Scholar
• Kawano K, Tsuda N, Waki K, et al. Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy. Cancer Sci. 2015;106:1111–1117. doi:10.1111/cas.12729.
   PubMed Web of Science ®Google Scholar
• Takahashi R, Ishibashi Y, Hiraoka K, et al. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients. Cancer Sci. 2013;104:1285–1294. doi:10.1111/cas.12226.
   PubMed Web of Science ®Google Scholar
• Komatsu N, Matsueda S, Tashiro K, et al. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer. 2012;118:3208–3221. doi:10.1002/cncr.26636.
   PubMed Web of Science ®Google Scholar
• Sakamoto S, Yoshitomi M, Yutani S, et al. Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination. Hum Vaccin Immunother. 2015;11:2784–2789. doi:10.1080/21645515.2015.1075107.
   PubMed Web of Science ®Google Scholar
• Waki K, Yamada T, Yoshiyama K, et al. PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. Cancer Sci. 2014;105:1229–1235. doi:10.1111/cas.12502.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Mok T, Postmus PE. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2013;39:252–260. doi:10.1016/j.ctrv.2012.05.003.
   PubMed Web of Science ®Google Scholar
• Cromwell I, van der Hoek K, Malfair Taylor SC, et al. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis. Lung Cancer. 2012;76:472–477. doi:10.1016/j.lungcan.2011.12.003.
   PubMed Web of Science ®Google Scholar
• von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32:4012–4019. doi:10.1200/JCO.2013.54.5392.
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–489. doi:10.1038/nature10673.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29:4828–4836. doi:10.1200/JCO.2011.38.0899.
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–1570. doi:10.1126/science.1203486.
   PubMed Web of Science ®Google Scholar
• Bei R, Scardino A. TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy. J Biomed Biotechnol. 2010;2010:1–12. doi:10.1155/2010/102758.
   Google Scholar
• Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol. 1999;17:51–88. doi:10.1146/annurev.immunol.17.1.51.
   PubMed Web of Science ®Google Scholar
• Chen W, McCluskey J. Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv Cancer Res. 2006;95:203–247. doi:10.1016/S0065-230X(06)95006-4.
   PubMed Web of Science ®Google Scholar
• Pilla L, Rivoltini L, Patuzzo R, et al. Multipeptide vaccination in cancer patients. Expert Opin Biol Ther. 2009;9:1043–1055. doi:10.1517/14712590903085109.
   PubMed Web of Science ®Google Scholar
• Sanchez AM, Denny TN, O’Gorman M. Introduction to a special issue of the journal of immunological methods: building global resource programs to support HIV/AIDS clinical trial studies. J Immunol Methods. 2014;409:1–5. doi:10.1016/j.jim.2014.05.016.
   PubMed Web of Science ®Google Scholar
• Chauvat A, Benhamouda N, Gey A, et al. Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans. Hum Vaccin Immunother. 2014;10:104–113. doi:10.4161/hv.26593.
   PubMed Web of Science ®Google Scholar
• Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother. 2013;62:137–147. doi:10.1007/s00262-012-1317-2.
   PubMed Web of Science ®Google Scholar
• GuhaThakurta D, Sheikh NA, Fan LQ, et al. Humoral immune response against nontargeted tumor antigens after treatment with Sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res. 2015;21:3619–3630. doi:10.1158/1078-0432.CCR-14-2334.
   PubMed Web of Science ®Google Scholar
• Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8:351–360. doi:10.1038/nrc2373.
   PubMed Web of Science ®Google Scholar
• Bijker MS, Van Den Eeden SJ, Franken KL, et al. CD8+ CTL priming by exact peptide epitopes in incomplete Freund’s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol. 2007;179:5033–5040.
   PubMed Web of Science ®Google Scholar
• Toes RE, Offringa R, Blom RJ, et al. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A. 1996;93:7855–7860.
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res. 2008;14:169–177. doi:10.1158/1078-0432.CCR-07-1881.
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361:1838–1847. doi:10.1056/NEJMoa0810097.
   PubMed Web of Science ®Google Scholar
• Leffers N, Lambeck AJ, Gooden MJ, et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer. 2009;125:2104–2113. doi:10.1002/ijc.24597.
   PubMed Web of Science ®Google Scholar
• Welters MJ, Kenter GG, Piersma SJ, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res. 2008;14:178–187. doi:10.1158/1078-0432.CCR-07-1880.
   PubMed Web of Science ®Google Scholar
• Yadav M, Jhunjhunwala S, Phung QT, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515:572–576. doi:10.1038/nature14001.
   PubMed Web of Science ®Google Scholar
• Carreno BM, Magrini V, Becker-Hapak M, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348:803–808. doi:10.1126/science.aaa3828.
   PubMed Web of Science ®Google Scholar